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ligand that cannot bind to the natural receptor but can
bind to an appropriately modified form of the receptor.
For many applications it is also desirable to engineer
“orthogonal receptors,” which exclusively bind the syn-
thetic ligand and not the natural ligand [1]. In practice,
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engineered ligand-receptor pairs need not be strictly
orthogonal but need only be functionally orthogonal.Summary
Functionally orthogonal receptors can be defined as
engineered receptors that are not activated by concen-The reengineering of protein-ligand (or enzyme-sub-
trations of the natural ligand found endogenously. Instrate) interfaces using a combination of chemical and
other words, a modified receptor can still have somegenetic methods has become an increasingly common
measurable affinity for its natural ligand but would betechnique to create new tools to manipulate and study
unaffected by the natural ligand if the endogenous li-biological systems. Many applications of ligand recep-
gand concentration is well below its Kd (KM or EC50) (Fig-tor engineering require that the engineered ligand and
ure 1A). The modified receptor’s reduced affinity for thereceptor function independently of endogenous ligands
natural ligand can be thought of as the receptor’s abilityand receptors. Engineered ligands must selectively
to discriminate against the endogenous ligand. Simi-interact with modified receptors, and modified recep-
larly, a ligand can be regarded as being functionallytors must effectively discriminate against endogenous
orthogonal if it has sufficiently higher affinity for theligands. A variety of chemical design strategies have
modified receptor than the endogenous receptor, suchbeen used to reengineer ligand-receptor interfaces.
that there is a significant range of ligand concentrationsThe advantages and limitations of various strategies,
wherein the modified receptor is exclusively occupiedwhich involve the manipulation of hydrophobic, polar,
(Figure 1B). The difference in affinity for the modifiedand charged residues, are compared. New design
receptor versus the wild-type can be regarded as astrategies and potential applications of ligand-recep-
property of the ligand, the ligand’s receptor selectivity.tor engineering are also discussed.
For many applications, it is necessary for both the de-
signed ligand to selectively bind the engineered recep-
tor, not the wild-type, and for the engineered receptorProtein-ligand engineering is an increasingly important
to not bind the natural ligand.technique for creating new tools for the manipulation and
study of biological systems. For almost two decades,
chemical and genetic methods for manipulating the mo- Steric Complementation
lecular structures of small molecule-protein interfaces Bumps and Holes
have been used to alter enzyme substrate specificity or
One of the easiest ways to envision creating an orthogo-
to generate new ligand-receptor pairs that can selec-
nal ligand-receptor pair is to modify the complementary
tively regulate transcription, apoptosis, genetic recom-
shape of the ligand-receptor interface such that the en-
bination, signal transduction, or motor protein function
gineered ligand is too large to fit within the binding site
(For reviews see [1–3]). Whereas many recent reviews
of the wild-type receptor but can bind to a modified
have focused on the many applications of ligand-recep-
form of the receptor whose binding site has been appro-
tor engineering, this review aims to provide a general
priately enlarged by mutagenesis (Figure 2A). The term
overview of the different design strategies that have been
“bumps and holes” was first used to describe an engi-
used in such studies, in terms of principles of molecular
neered cyclosporin/cyclophilin interface and the term
recognition and protein engineering. For simplicity, ge-
has become almost synonymous with protein-ligand en-
neric discussions will refer to the binding of ligand-recep-
gineering in the common scientific vernacular [4]. How-
tor pairs. However, it should be understood that the same
ever, not all bumps and holes are alike, and many other
principles should apply to enzyme-substrate pairs, (i.e.,
ligand design strategies have been employed to gener-
substrate/transition state binding), as well. Throughout
ate unique protein-ligand interfaces.
this review, examples will be cited that illustrate specific
One common limitation to this strategy of ligand-
design principles, although the success of any particular
receptor engineering is that whereas it is relatively
design strategy may be dependent on a number of fac-
straightforward to create a “bumped ligand” that does
tors beyond the “design strategy.” Thus, such examples
not fit in the endogenous receptor, the “hole-modified”
should only be regarded as a qualitative guide.
receptor often retains significant affinity for the natural
ligand because the generation of a hole does not actively
Orthogonal and Functionally Orthogonal discriminate against the natural ligand (Figure 2B). For
Ligand-Receptor Pairs example, bumped cyclosporin analogs can selectively
For most applications of ligand-receptor engineering, bind to hole-modified cyclophilin mutants generated by
one generally seeks to design an “orthogonal ligand,” a a Phe→Ala substitution in combination with one or two
other mutations (hCyP(Ser99→Thr/Phe113→Ala) and
hCyP(Ser99→Thr/Phe113→Ala/Cys115→Met)) (Figure 3).1Correspondence: johnkoh@udel.edu
Chemistry & Biology
18
Figure 1. Definitions of Selectivity, Discrimi-
nation, and Functionally Orthogonal
(A) A functionally orthogonal receptor is not
activated by endogenous concentrations of
the natural ligand.
(B) A functionally orthogonal ligand is one ca-
pable of activating a modified receptor over
a significant concentration range without sig-
nificantly activating endogenous receptors.
However, these modified receptors bound the natural Dual Bump-Hole/Hole-Bump Modifications
One obvious strategy to create mutually orthogonal li-cyclosporin with almost equal affinity as the wild-type
cyclophilin [4]. In another example, bumped ATP ana- gand-receptor pairs has been to create dual bump and
hole plus hole and bump combinations to provide mutu-logs have been created that selectively bind modified
forms of myosin-I modified by a Tyr61→Gly mutation ally orthogonal ligand receptor pairs (Figure 4A). This
strategy was recently demonstrated by Shokat et al.,within the ATP binding site. However, the modified re-
ceptor had nearly wild-type affinity for ATP [5]. Similarly, who designed orthogonal nucleotide triphosphate/ki-
nase pairs [7]. In this case, substrate selectivity andhole-modified forms of v-Src, by either Ile338→Ala or
Ile338→Gly mutations, exhibited only a less than 7-fold receptor discrimination could be engineered into the
new receptor. However, the new ligand-receptor pairreduction in ATP affinity [6]. These studies suggest that
the bump and hole strategy is quite successful at gener- had greatly reduced catalytic efficiency. While in princi-
ple it is possible to apply bump and hole strategies toating ligands that selectively bind modified receptors,
but often the modified receptors do not appreciably make both a ligand and a receptor that are mutually
orthogonal to the endogenous ligand-receptor pair,discriminate against their natural ligands.
It should be noted that not all applications of ligand- these results suggest that it may be difficult to maintain
high affinity or catalytic efficiency when grossly modi-receptor engineering require that the receptor not be
able to bind the endogenous ligand. Receptors with fying the protein-ligand interface by multiple opposing
mutations. The use of random mutagenesis/selectionfunctionally silent mutations that can partially label spe-
cific downstream molecular targets or which can be techniques may be able to overcome these limitations [7].
selectively inhibited by unique inhibitors are powerful
tools in chemical biology [1]. Nonetheless, it is often Polar Ligand-Receptor Interactions
Can Provide Specificitydesirable and necessary to engineer systems such that
both ligand and receptor are functionally orthogonal to Reversal of Hydrogen Bonding Patterns
Classic studies in molecular recognition and proteinthe endogenous system. The challenge is to select mu-
tations to the receptor that actively discriminate against folding suggest that polar interactions, hydrogen bonds,
and ion pairing are often associated with conferringbinding the natural ligand and yet can be recognized by
synthetic ligands with high affinity and selectivity. specificity to molecular recognition processes [8, 9].
Figure 2. Altering Steric Complementarity by
Bump and Hole Engineering
(A) Generation of an orthogonal ligand by
bump and hole engineering.
(B) The ligand selectively binds only the engi-
neered receptor, but the engineered receptor
may still bind the endogenous ligand.
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Figure 5. Key GTP/EF-Tu Interactions
Reversal of hydrogen bonding pairs was used to convert the GTPase
EF-Tu (top) to a XTPase (bottom) [10].
Figure 3. Key Cyclosporin/Cyclophilin Interactions
Bump and hole modifications alter the hydrophobic groups at the hydrogen bond donor (Figure 5). The modified receptor
interface of Cyclosporin (CsA) and cyclophilin (CyP) [4]. shows substantially reduced affinity for the natural sub-
strate GTP, which if bound would form a donor-to-donor
mismatch. For analogous mutations in Ha-Ras p21, an
Asp→Asn substitution reduces the GTP binding affinityHwang and Miller had one of the early and most suc-
by a factor of almost 103 but has a XTP affinity similarcessful ligand-receptor design strategies for reengineer-
to the wild-type receptor’s affinity for GTP [11]. Thus,ing GTPases to selectively use xanthine-nucleoside tri-
altering hydrogen bonding patterns is one successfulphosphates (XTP) as substrates by manipulating
strategy to engineer selective ligands for mutant recep-hydrogen bonding interactions [10]. The hydrogen
tors that discriminate against their natural ligands orbonding pair at the ligand-receptor interface of EF-Tu
substrates. However, it is often the case that the aminois reversed by exchanging a hydrogen bond acceptor
acid side chains involved in hydrogen bonding are notfor a hydrogen bond donor and vice versa (Figure 4B).
amenable to reversing hydrogen bond patterns by sim-In this case, the carboxylate side chain of Asp138, which
ple substitution for another amino acid. In such cases,contributes two hydrogen bond acceptors to the pro-
polar interactions may also be exchanged for nonpolar.tein-ligand interface, is mutated to the amide of aspara-
Manipulation of Charged Interactionsgine, which effectively exchanges one acceptor for a
The manipulation of charged groups that are a part of
or adjacent to the ligand-receptor interface can also
have a significant effect on selectivity and discrimina-
tion. One of the principle advantages of this approach
is that charged groups that do not directly contact the
ligand can still influence ligand binding through space.
Kampoor and Mitchson modified several conserved res-
idues in the vicinity of N6 of the adenine of ATP in the
ATP binding pocket of kinesin [12]. Within the obvious
limitations of comparing different mutations at different
positions within the protein, it is interesting to note that
mutation of neutral residues Thr94→Ala, Pro17→Gly re-
duced the activity with ATP by only 60% of the wild-
type, whereas modification of Arg14 (Arg14→Ala), which
indirectly contacts the ligand through intervening water
Figure 4. Selective Ligand Receptor Pairs May Be Created by Modi- molecules, reduces the activity to below 1% of wild-
fication of Neutral Interactions
type. In this case, the “hole” created by deleting the
(A) Dual bump-hole/hole-bump modified receptors may provide im- cationic arginine side chain could be complemented by
proved substrate selectivity and receptor discrimination.
a hydrophobic cyclopentyl group appended to N6 of(B) Reversal of hydrogen bonding patterns can afford orthogonal
adenosine of ATP. The process of exchanging polarligand-receptor pairs without grossly affecting the shape of the li-
gand-receptor interface. ligand-receptor interactions with hydrophobic pairs can
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Figure 7. Selective Ligand-Receptor Pairs May Be Created by Mod-
ification of Ion-Pairs
Figure 6. Key Lactate/Lactate Dehydrogenase Interactions (A) Charge to neutral substitutions are often effective at providing
selective interactions because unpaired counter ions are ineffec-The introduction of a salt bridge converts a lactate dehydrogenase
tively compensated for the cost of desolvation in the mismatched(top) to a malate dedehydrogenase (bottom)[13].
ligand-receptor pairs (yellow).
(B) Charge reversal may offer significant selectivity but is often asso-
ciated with substantially lower affinity.
indirectly provide selectivity and discrimination by leav- (C) An intramolecular salt bridge interaction can be converted to an
intermolecular protein-ligand salt bridge.ing polar groups insufficiently compensated for the cost
of desolvation in the mismatched complexes.
Introduction of New Ion Pairs
One of the early examples of reengineering enzyme sub- tively activated by a neutral but longer ethyl amide of
retinoic acid; the receptor’s activity with the natural li-strate specificity reported by Holbrook involved con-
verting a lactate dehydrogenase to a malate dehydroge- gand tRA could not be determined due to significant
endogenous concentrations of the wild-type receptornase by introducing a charged residue that can
selectively ion pair with malate [13]. The Gln102→Arg [16].
Charge Reversalmutant displayed a 30-fold higher KM for pyruvate and
a 25-fold decrease in KM for oxaloacetate (Figure 6). This The reported successes of modifying receptors to dis-
criminate against their natural ligands by “neutralizing”example illustrates that new polar interactions can be
introduced to change substrate specificity. The arginine charged residues or reversing hydrogen bonding part-
ners suggest that reversing the polarity of ion pairingsubstitution does not dramatically reduce the enzymes
affinity for pyruvate based on the measured KMs; how- interactions may also be a successful strategy to alter
ligand binding or enzyme substrate specificity (Figureever, this is a remarkably selective catalytic system
when one compares Kcat/KM. Similarly, Perham de- 7B). Kirsh successfully reengineered an aspartyl amino-
transferase to preferentially accept L-arginine as a sub-scribed a system wherein arginine substitutions within
the cofactor binding site were used to convert pyruvate strate by substituting the cationic residue Arg292, in-
volved in ion pairing to substrate side chain, to andehydrogenase from a NAD-dependent enzyme to an
NADPH-dependent enzyme [14]. anionic aspartic acid [17]. In this case, the selectivity
was modest, 16-fold based on Kcat/KM ratios, and theIon Pair Neutralization
Whereas engineering high-affinity interactions by intro- modified enzyme was 43,000 times less active than the
wild-type enzyme with its natural substrate.ducing ion pairs into the ligand-receptor interface can be
difficult, the removal of existing ion pairing interactions Similarly, in the complex of retinoic acid (tRA) and the
retinoic acid receptor (RAR), the carboxylate group ofbetween ligand and receptor can provide substantial
discrimination against the natural substrate (Figure 7A). retinoic acid is bound via a salt bridge to Arg278. A
cationic guanidine-functionalized retinol derivativeFor example, manipulation of an intermolecular salt
bridge between the carboxylate group of retinoic acid could preferentially activate a engineered receptor
RAR(S289D), which presumably forms a salt bridge oftRA and the guanidine group of Arg269 of RAR has
been used to alter the ligand binding specificity of a opposite polarity of the wild-type complex [16]. How-
ever, this charge-reversed ligand receptor pair alsoligand-dependent transcriptional regulator [15]. In this
case, a cationic to neutral/polar substitution, Arg269→Gln, shows dramatically reduced activity compared to the
wild-type ligand-receptor pair. The general phenome-caused a more than 700-fold reduction in activity for
retinoic acid and increased its activity toward the struc- non, that reversal of salt bridge pairs does not afford
structures (or complexes) of equal stability, has beenturally similar but neutral ligand retinol by over 110-fold.
A similar charge neutralization strategy has been applied well documented in the protein folding/stability literature
[17–20]. Warshel has suggested that the partners in-in conjunction with a bump and hole modification to the
closely related receptor subtype RAR. In this case, the volved within an intermolecular salt bridge are also sta-
bilized by multiple interactions within the protein-liganddouble mutant RAR(S289G, R278E) could be selec-
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Figure 9. New Strategies in Protein-Molecule Engineering
(A) New binding sites can be engineered into both protein-ligand
(enzyme-substrate) and protein-protein interfaces.
(B) The introduction of complementary reactive functionality may
offer a new approach to increasing selectivity and high avidity.
variant by replacing the carboxylate group lost upon
Glu→Ala substitution with one covalently attached to
the ligand (Figure 8). They showed that carboxylate-Figure 8. Key Estradiol/Estrogen Receptor Interactions
functionalized analogs of estradiol could also effectivelyAn intramolecular protein salt bridge which provides hydrogen bind-
ing interactions to bound estradiol (E2) in hER (top) can be ex- complement the Glu353→Ala mutant with a greater than
changed for an intermolecular salt bridge (bottom) [23]. 16-fold selectivity for the mutant over wild-type [23]. Shi
et al. have recently confirmed their results using native
ER. Their best-matched carboxylate-functionalized li-
gand has a 95-fold preference for ER(E353A) over thecomplex, which are lost or may become destabilizing
to the complex when the salt bridge polarity is reversed wild-type receptor (J.T.K. and Y. Shi, personal communi-
cation). The high affinity and increased selectivity[20, 21]. This suggests that while charge reversal may
in principle be capable of producing orthogonal ligand- achieved by exchanging an intramolecular protein salt
bridge for an intermolecular protein ligand salt bridgereceptor pairs, the general approach may in general be
limited by a substantially reduced affinity of the modified is likely due to combining both steric and electrostatic
interactions (Figure 7C).complex.
Polar/Charged Group Exchange The advantage of this “polar-group exchange” strat-
egy for manipulating ion-paired charged residues com-Two recent reports by Tedesco et al. and Shi et al. have
explored two different successful strategies to reengin- pared to a “charge-reversal” strategy is that the new
ligand receptor complex effectively differs from the wild-eer the interactions between estradiol (E2) and the estro-
gen receptor. Both involve the modification of Glu353, type complex only in the covalent connectivity of the
same charged functional groups and therefore pre-which forms an intramolecular protein salt bridge with
Arg394 as well as forms hydrogen bonds to the phenol serves the dipolar and other stabilizing interactions
found in the native ligand-receptor complex. The gener-hydroxyl of E2 (Figure 8) [22, 23]. Together, these studies
allow a more direct comparison of different strategies ality of this approach remains to be demonstrated.
Clearly, not all ligand binding sites are conveniently lo-for complementing the same receptor mutations.
Tedesco et al. compared the relative potencies of cated adjacent to structural salt bridges, although in
principle this strategy should also work for other neutralestradiol for three mutants at positions 353. Substitution
of Glu353 for Asp, Ser or Ala resulted in a 5-, 150-, or polar interactions. Furthermore, not all proteins will tol-
erate the loss of a structurally stabilizing salt bridge. Ina 400-fold reduction in potency of the natural ligand E2,
again suggesting that replacement of charge residues general, one should only expect to obtain high-affinity
ligands when the polar groups in the engineered com-with neutral and nonpolar ones may be a general strat-
egy for generating modified receptors which signifi- plex are precisely matched and when energetic cost of
desolvating the polar partner on binding is not too largecantly discriminate against their natural ligands [22].
Tedesco et al. evaluated eight estradiol analogs that compared to the favorable pairing interactions gained
upon binding.contain neutral, hydrophobic, or neutral hydrophilic pen-
dant groups in place of the phenol hydroxyl effectively Creating De Novo Binding Sites
at Ligand-Receptor Interfacesreplacing the anionic partner of a salt bridge with a
hydrophobic group. Their two best-matched hydropho- An alternative approach to engineering new complemen-
tary ligand-receptor interfaces is to engineer de novo li-bic extensions could activate ER(E353A) mutant with
9 and 34 times higher potency than the wild-type ER gand binding sites into the ligand-receptor or protein-
protein interfaces. (Figure 9A). One of the first examples[22]. Shi et al., using a strategy they termed “polar-group
exchange,” complemented the same mutation in an ER in this area was demonstrated by Craik et al., who engi-
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neered a new metal binding site at the enzyme-substrate mimic could be designed to complement a mutationally
impaired receptor associated with the human geneticinterface at the P2 site of trypsin (Tn) by introducing
metal-coordinating functional groups into both the en- disease resistance to thyroid hormone (RTH) [28]. Al-
though applications of such strategies to the treatmentzyme and the substrate [24]. The Tn(Asn143→His/
Glu151→His) mutant conditionally hydrolyzed peptide of human disease are still many years away, this study
emphasizes the need to understand and develop multi-substrates that contain a histidine only in the presence
of added nickel ions. ple strategies to complement receptor mutations, which
discriminate against their natural ligands.Schultz et al. recently demonstrated that a binding
cavity for a neutral small molecule could be engineered
into a protein-protein interface [25]. Binding and signal Acknowledgments
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